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Abstract 
Background: The absence of nocturnal blood pressure dipping (ND) identified by 24‑h ambulatory blood pres‑
sure monitoring (ABPM) correlates with a worse cardiovascular prognosis. The renin–angiotensin system influences 
blood pressure levels and the occurrence of target organ damage (TOD). Thus, the aim of this study was to correlate 
the angiotensin‑converting enzyme gene (ACE) insertion/deletion (I/D) polymorphism with the 24‑h blood pressure 
profile and TOD in hypertensive individuals.
Methods: 155 non‑diabetic hypertensive individuals on antihypertensive treatment underwent ABPM. Peripheral 
blood samples were drawn for biochemistry and genetic analysis of the ACE I/D polymorphism by polymerase chain 
reaction. ND was defined as ≥10 % differences in the mean systolic blood pressure (BP) during wakefulness and sleep.
Results: There were no differences in clinical or biochemical variables or TOD in respect to ND status, except for 
higher BP levels during sleep (p < 0.001) in non‑dippers. There was significant difference in the prevalence of left 
ventricular hypertrophy (LVH) between ACE genotypes (II: 13.0 %; ID: 34.1 %; DD: 46.5 %; p value = 0.024) with an 
increased risk in carriers of the DD genotype (OR = 5.80; IC 95 % 1.50–22.44; p value = 0.011). Carriers of the D 
allele had higher systolic BP during wakefulness and by ABPM (p < 0.05), higher left ventricular mass (117.3 ± 50.0 
vs. 100.3 ± 25.7; p value = 0.017) and higher prevalence of LVH (37.4 vs. 12.5 %; OR = 4.14; 95 % IC: 1.17–14.65; p 
value = 0.028), compared to the II genotype.
Conclusions: The DD genotype is associated with a higher prevalence of LVH. The presence of the D allele appears 
to be associated with higher mean 24‑h and wake systolic BP measured by ABPM in hypertensive patients under 
antihypertensive treatment.
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Background
Hypertension (HT) is a highly prevalent disease associ-
ated with increased risk of target organ damage (TOD), 
including myocardial infarction, stroke and left ventric-
ular hypertrophy (LVH). Changes in blood pressure are 
influenced by daily activities and interactions with neu-
rohumoral, behavioral and environmental factors. Under 
physiological conditions, there is a drop in the blood 
pressure (BP) between wakefulness and sleep, a phenom-
enon known as nocturnal blood pressure dipping (ND). 
The absence of ND is associated with TOD and higher 
mortality [1–4].
Due to the multifactorial etiology of HT, many 
researchers are studying the association between genetic 
polymorphisms and HT and its complications. This 
research studied the angiotensin-converting enzyme 
(ACE) gene insertion/deletion (I/D) polymorphism, 
which is characterized by the presence (insertion) or 
absence (deletion) of an Alu repetitive sequence of 287 
base pairs (bp) in intron 16 of the ACE gene [5]. The vari-
ability in plasma ACE levels is directly related to the I/D 
polymorphism; the I allele is associated with a reduced 
level of this enzyme and lower concentrations of angio-
tensin II in tissues [5], a condition that apparently pro-
tects against TOD.
The ACE I/D polymorphism is linked to risk for myo-
cardial infarction and cardiovascular events [6–9], LVH 
[10–12], microalbuminuria [11, 13, 14], thoracic aortic 
aneurysm in patients with bicuspid or tricuspid aortic 
valves [15], pregnancy hypertensive disorders [16, 17], 
and hypertensive emergency [18]. Moreover, this poly-
morphism is related to inter-individual differences in 
BP response, for example, a low dose of the hydrochlo-
rothiazide diuretic produced greater BP reductions in 
men with the DD genotype and women with the II geno-
type [19]. Therefore, this polymorphism may also have a 
role in the genesis of TOD, which is commonly found in 
hypertensive individuals. Recently, a meta-analysis of 44 
articles involving 12,616 subjects, demonstrated the con-
tribution of the I/D polymorphism to susceptibility for 
LVH [20].
The findings reported in the literature in respect to 
the relationship of this polymorphism with BP levels 
and TOD are controversial [14, 21–31]. Thus, this study 
aimed to characterize the anthropometric, biochemical, 
and echocardiographic data and blood pressure profile of 
non-diabetic hypertensive individuals and to investigate 
the influence of the ACE I/D polymorphism on 24-h BP 
levels and on TOD.
Methods
This project was approved by the Research Ethics Com-
mittee of the State Medical School in São José do Rio 
Preto (no. 169/2008). All participants were informed 
about the purpose of the work and gave their written 
informed consent before participating in the research. 
This was a cross-sectional study, which enrolled 155 
hypertensive individuals followed-up at a university 
hospital outpatient clinic. The exclusion criteria were 
age under 40  years, history of valvular disease, systolic/
diastolic dysfunction, diabetes mellitus (DM), body mass 
index (BMI) ≥35  kg/m2, creatinine clearance <30  mL/
min/m2, and secondary hypertension.
An investigative protocol was used to collect informa-
tion on age, gender, medicines taken, and comorbidi-
ties. Data regarding DM, strokes, MI, and dyslipidemia 
(DLP) were used to assess comorbidities. Patients who 
had presented with two or more fasting glycemia lev-
els ≥126  mg/dL or altered oral glucose tolerance test 
(≥200 mg/dL) were excluded [32]. History of strokes was 
based on clinical history, medical records, and the pres-
ence of sequels. The diagnosis of MI was based on clinical 
history and confirmed by an analysis of medical records 
that described enzymatic alterations (troponin and 
CK-MB), and electrocardiographic alterations suggestive 
of coronary ischemia and treatment. DLP was identified 
by total cholesterol (TC), high-density lipoprotein choles-
terol fraction (HDL-c) and triglycerides (TG) levels after 
12 h of fasting [33]. The following reference values were 
adopted: TC <200  mg/dL, HDL-c >40  mg/dL, low-den-
sity lipoprotein cholesterol fraction (LDL-c) <130 mg/dL 
and TG <150 mg/dL. The LDL-c fraction was calculated 
using the formula: LDL-c =  TC −  HDL-c −  TG/5 (for 
TG <400  mg/dL) [34]. DLP was defined for individuals 
with alterations in the aforementioned parameters and 
those who were under treatment with HMG-CoA reduc-
tase inhibitors or other hypolipemic drugs.
Weight and height were measured and BMI was calcu-
lated using the formula: BMI = weight (kg)/height (m)2. 
Besides stroke and MI, TOD was also considered as the 
presence of microalbuminuria and left ventricular hyper-
trophy (LVH). Microalbuminuria was characterized as 
the average of two 24-h urinary albumin excretion rates 
≥20 μg/min.
Echocardiographic analysis
All echocardiographic examinations were performed 
by the same experienced echocardiographer. M-Mode 
echocardiograms were performed under cross-sectional 
control, with the patient in partial left decubitus posi-
tion, using an Philips HD15 PureWave ultrasound system 
and S5-2 Broadband Sector Array Transducer (Andover, 
MA 01810-1099 -USA) with 2.5- to 3.5-MHz mechanical 
transducers. Left ventricular (LV) dimensions and mass 
were assessed from 2D-guided M-mode tracings accord-
ing to American Society of Echocardiography (ASE) 
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recommendations. M-mode measurements were aver-
aged from three cycles. LV end-systolic, end-diastolic, 
and stroke volumes were calculated. Ejection fraction was 
calculated from derived volumes with computed based 
on the “cubed” or “Teichholtz” equations, but only in the 
absence of asynergy. 2-D method of Simpson calculated 
was performed in distorted ventricles [35]. To evaluate 
the segmental LV function, the ASE recommends adopt 
17-segment model scored as 1: normal, 2: hypokinetic, 
3: akinetic, 4: dyskinetic, and 5: aneurysmal (diastolically 
deformed). The ASE also recommends that wall motion 
be judged by segmental thickening in addition to endo-
cardial motion.
The ASE-recommended formula for estimation of 
LV mass from LV linear dimensions was performed to 
define LVH. Left ventricular hypertrophy was defined 
as left ventricular mass index (LVMI) >115 g/m2 in men 
and >95 g/m2 in women [35]. Relative wall thickness was 
calculated as twice the posterior wall in diastole divided 
by internal diastolic diameter and was used to estimate 
the LV geometry concentric (RWT ≥0.42) or eccentric 
(RWT ≤0.42) hypertrophy [36]. The diastolic dysfunc-
tion was evaluated by the ASE and the European Asso-
ciation of Echocardiography (EAE) recommendations. 
They apply an algorithm that takes into account not only 
the E/A ratio, but the deceleration time of the E wave, 
the early and late velocities of the mitral annulus meas-
ured by tissue Doppler (e′ and a′), the left atrial volume, 
the pattern of pulmonary vein flow, and the duration of 
reversed flow into the pulmonary veins during atrial con-
traction. The algorithm includes the parameter E/e and 
also investigates the color M-mode velocity of propaga-
tion of the mitral inflow toward the apex. A rapid veloc-
ity coincides with normal diastolic function, whereas a 
slower velocity indicates delayed relaxation [37].
Ambulatory blood pressure monitoring
BP levels were obtained by ambulatory blood pressure 
monitoring (ABPM) taking into account the average BP 
over a 24-h period and differences in the mean awake 
and sleep BP (presence or absence of ND). ABPM was 
performed using the Spacelabs 90207 equipment. The 
equipment was fitted during the daytime and the patient 
remained with the unit for a period of 24 h. The moni-
toring process was carried out without patients changing 
their normal daily activities. The device was programmed 
to record BP levels at 15-min intervals during daytime, 
and 20-min intervals at night. All participants were 
instructed to make notes on their daily activities includ-
ing meal times, bedtime, and the timing of medications 
and symptoms. Thus, periods of wakefulness and sleep 
were defined based on the time recorded by patients in 
their diaries. ND was defined as ≥10 % drop in systolic 
BP from wakefulness to sleep [38]. Individuals were clas-
sified as dippers (with ND) or non-dippers (without ND). 
In addition, patients were classified according to the ACE 
I/D genotypes. Subsequently, patients were grouped as 
carriers of the D allele (ID and DD genotypes) and com-
pared to those homozygous for the I allele.
Genetic analysis
Peripheral blood was drawn for the extraction of DNA. 
The analysis of the genetic variants of the ACE gene was 
performed by extracting genomic DNA from leukocytes 
[39], with DNA amplification by conventional poly-
merase chain reaction (PCR) [40]. The amplification of 
the polymorphic segment to analyze the ACE I/D poly-
morphism was performed by initial denaturation with 
30 cycles at 94  °C for 1 min, 58  °C for 1 min, 72  °C for 
1.5  min, and a final extension of 72  °C for 10  min [40]. 
Since the amplification of the I allele (490 bp) is less effi-
cient than that of the D allele (190 bp), the specificity of 
the DD genotyping was increased by amplifying all DD 
samples using a pair of specific primers for the insertion 
sequence, with the presence of a DNA fragment of 335 bp 
confirming the ID genotype [40]. In this case, PCR was 
performed with 35 cycles at 94 °C for 30 s, 69 °C for 45 s, 
72 °C for 2 min, and a final extension of 72 °C for 7 min. 
The amplification products were subjected to electropho-
resis on 1 and 1.8 % agarose gel for samples amplified by 
the first reaction, and the second reaction, respectively, 
followed by staining using ethidium bromide and visuali-
zation under ultraviolet light.
Statistical analysis
Descriptive analysis was conducted for the quantitative 
variables with the presentation of mean values and stand-
ard deviations. The Student t test and ANOVA were used 
to analyze quantitative variables and the χ2 test for quali-
tative variables. The allelic and genotypic frequencies 
were compared between the groups using the χ2 test. The 
influence of alleles and genotypes on 24-h BP and TOD 
was detected by calculating cross-products [Odds ratio 
(OR)] with a 95 % confidence interval (95 % CI). All sta-
tistical analyses were performed using the Minitab 15.0 
computer program. An alpha error greater than 5  % (p 
value <0.05) was considered statistically significant.
Results
The anthropometric, biochemical, and echocardio-
graphic data and blood pressure profile of the sam-
ple are presented in Table  1. The mean time of HT 
(16.0  ±  10.1  years), BP levels above the recommended 
range, and increased values of BMI (28.8  ±  4.9  kg/m2) 
and microalbuminuria (58.1 %) stand out in this sample. 
On comparing individuals with and without ND, there 
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were no differences between clinical, and biochemi-
cal variables or TOD except for lower BP levels during 
sleep (p  <  0.001) in patients with ND (Table  2). There 
was not systolic and diastolic ventricular dysfunction and 
neither significant areas of infarction scars in the evalu-
ated sample.
When grouped according to the genotype of the ACE 
I/D polymorphism, the groups did not significantly differ 
in respect to mean age, gender, BMI and duration of HT. 
There were no statistically significant differences between 
the three genotypes (II, ID, and DD) and mean 24-h BP 
by ABPM (Table 3). However, there was a significant dif-
ference in the prevalence of LVH between the ACE geno-
types (II: 13.0 %; ID: 34.1 %; DD: 46.5 %; p value = 0.024). 
By logistic regression (Table 4), carriers of the DD geno-
type had higher risk of LVH compared to those with the II 
genotype (OR: 5.8; 95 % CI 1.50–22.44; p value = 0.011). 
There was no significant difference between genotypes in 
respect to the other TOD investigated in this study.
Carriers of the D allele (ID and DD genotypes) had 
higher awake systolic BP and mean 24-h BP compared 
to those with the II genotype (p value  =  0.036 and p 
value  =  0.042, respectively) (Table  3) although there 
were no statistically significant differences between 
the three genotypes. Moreover, carriers of the D allele 
also had higher left ventricular mass (209.3  ±  87.1 
vs. 170.1  ±  48.0  g; p value  =  0.003), left ventricu-
lar mass index (117.3  ±  50.0 vs. 100.3  ±  25.7  g/m2; p 
value  =  0.017) and, consequently, higher prevalence of 
LVH (37.4 vs. 12.5  %; p value  =  0.019) than individu-
als with the II genotype. By logistic regression, D allele 
carriers had a three times higher risk of LVH than those 
with the II genotype (OR = 4.14; 95 % CI 1.17–14.65; p 
value = 0.028) (Table 4). The allelic and genotypic distri-
butions of the population were in balance according to 
the Hardy–Weinberg equilibrium (χ2 = 3.11; p > 0.05).
Discussion
This study demonstrates an association between the D 
allele of the ACE I/D polymorphism and increased BP, 
and a correlation of the DD genotype with higher preva-
lence of LVH in non-diabetic hypertensive patients who 
despite antihypertensive treatment have poorly con-
trolled BP.
Recently, there has been growing interest in association 
studies on the I/D polymorphism and ACE plasma lev-
els and, consequently, on angiotensin II concentrations. 
However, results of studies on this relationship in hyper-
tensive patients are controversial. Thus, while some case–
control studies did not confirm any association between 
the I/D polymorphism and HT [21, 23, 24, 27, 41], oth-
ers reported a higher frequency of the D allele [28, 31] 
and DD genotype in subjects with HT [22, 28–30]. In 
these cases, it is possible that the profile of the sample 
regarding age, gender and associated diseases may have 
influenced the distribution of ACE genetic variants. In 
Table 1 Anthropometric, biochemical, and  echocardio-
graphic variables, blood pressure profile and  drugs used 
by hypertensive patients
BMI body mass index, LVH left ventricular hypertrophy, ACE angiotensin‑
converting enzyme, DBP diastolic blood pressure, SBP systolic blood pressure, LV 
left ventricle
Variable Sample (n = 155)
Age (years) 63.2 ± 11.4
Gender (male/female) 66/89
Duration of hypertension (years) 16.0 ± 10.1
BMI (kg/m2) 28.8 ± 4.9
Smoker, n (%) 16 (10.3)
History of stroke, n (%) 35 (22.6)
History of myocardial infarction, n (%) 7 (4.5)
LVH, n (%) 52 (33.5)
Microalbuminuria, n (%) 90 (58.1)
Drugs
 Hypolipemiant, n (%) 71 (45.8)
 Aspirin, n (%) 59 (38.1)
 Diuretic, n (%) 129 (83.2)
 ACE inhibitor, n (%) 103 (66.5)
 Angiotensin II receptor antagonist, n (%) 22 (14.2)
 Calcium channel blocker, n (%) 65 (41.9)
 Beta‑blocker, n (%) 46 (29.7)
Blood pressure levels
 24‑h SBP (mmHg) 135.2 ± 17.4
 24‑h DBP (mmHg) 81.7 ± 11.0
 Daytime SBP (mmHg) 137.4 ± 17.6
 Daytime DBP (mmHg) 83.7 ± 11.8
 Nighttime SBP (mmHg) 129.0 ± 19.2
 Nighttime DBP (mmHg) 75.2 ± 11.8
 SBP dipping (%) 5.8 ± 8.3
 SBP dipping (%) 10.0 ± 9.1
Echocardiographic profile
 Septal thickness (mm) 10.1 ± 1.7
 Wall thickness (mm) 9.8 ± 2.9
 LV mass (g) 203.2 ± 83.4
 LV mass index (g/m2) 114.7 ± 47.4
Biochemical profile
 Fasting glycemia (mg/dL) 96.6 ± 15.6
 HDL‑cholesterol (mg/dL) 56.8 ± 16.1
 LDL‑cholesterol (mg/dL) 116.2 ± 88.2
 Total cholesterol (mg/dL) 187.3 ± 35.8
 Triglycerides (mg/dL) 133.5 ± 78.2
 Creatinine (mg/dL) 1.5 ± 1.7
 Microalbuminuria (µg/min) 33.6 ± 46.3
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Table 2 Studied variables and genotype distribution according to the nocturnal dipping
BMI body mass index, LVH left ventricular hypertrophy, ACE angiotensin‑converting enzyme, DBP diastolic blood pressure, SBP systolic blood pressure, LV left ventricle, 
NS non‑significant (p > 0.05)
Variable Dippers (n = 50) Non-dippers (n = 105) p value
Age (years) 62.8 ± 12.0 63.5 ± 11.1 NS
Gender (Male/Female) 22/28 44/61 NS
Duration of hypertension (years) 14.7 ± 11.1 16.6 ± 9.6 NS
BMI (kg/m2) 28.3 ± 4.8 29.0 ± 5.0 NS
Smoker, n (%) 6 (12.0) 10 (9.5) NS
History of stroke, n (%) 12 (24.0) 23 (21.9) NS
History of myocardial infarction, n (%) 1 (2.0) 6 (5.7) NS
LVH, n (%) 16 (34.0) 36 (34.6) NS
Microalbuminuria, n (%) 26 (52.0) 64 (60.9) NS
Drugs
 Hypolipemiant, n (%) 18 (36.0) 53 (50.5) NS
 Aspirin, n (%) 15 (30.0) 44 (41.9) NS
 Diuretic, n (%) 44 (88.0) 85 (80.9) NS
 ACE inhibitor, n (%) 31 (62.0) 72 (68.6) NS
 Angiotensin II receptor antagonist, n (%) 7 (14.0) 15 (14.3) NS
 Calcium channel blocker, n (%) 24 (48.0) 41 (39.0) NS
 Beta‑blocker, n (%) 11 (22.0) 35 (33.3) NS
Blood pressure levels
 24‑h SBP (mmHg) 134.6 ± 19.0 135.6 ± 16.6 NS
 24‑h DBP (mmHg) 81.7 ± 9.9 81.7 ± 11.6 NS
 Daytime SBP (mmHg) 140.1 ± 19.6 136.1 ± 16.6 NS
 Daytime DBP (mmHg) 85.8 ± 10.4 82.7 ± 12.3 NS
 Nighttime SBP (mmHg) 118.7 ± 16.7 133.9 ± 18.4 <0.001
 Nighttime DBP (mmHg) 69.3 ± 9.2 78.0 ± 11.9 <0.001
 SBP dipping (%) 15.1 ± 4.6 1.4 ± 5.6 <0.001
 SBP dipping (%) 19.0 ± 5.7 5.6 ± 7.0 <0.001
Echocardiographic profile
 Septal thickness (mm) 10.1 ± 1.6 10.1 ± 1.8 NS
 Wall thickness (mm) 9.8 ± 1.5 9.9 ± 3.4 NS
 LV mass (g) 200.0 ± 64.4 204.8 ± 91.3 NS
 LV mass index (g/m2) 112.8 ± 31.8 115.6 ± 53.1 NS
Biochemical profile
 Fasting glycemia (mg/dL) 95.6 ± 18.9 97.1 ± 13.8 NS
 HDL‑cholesterol (mg/dL) 56.7 ± 15.2 56.8 ± 16.6 NS
 LDL‑cholesterol (mg/dL) 110.8 ± 22.7 109.2 ± 31.6 NS
 Total cholesterol (mg/dL) 193.6 ± 28.4 184.3 ± 38.6 NS
 Triglycerides (mg/dL) 138.8 ± 71.6 130.9 ± 81.4 NS
 Creatinine (mg/dL) 1.2 ± 0.3 1.3 ± 1.1 NS
 Microalbuminuria (µg/min) 38.2 ± 59.1 31.6 ± 39.7 NS
Genotype
 II, n (%) 8 (16.0) 16 (15.2) NS
 ID, n (%) 25 (50.0) 62 (59.0)
 DD, n (%) 17 (34.0) 27 (25.7)
Genotype combination
 II, n (%) 8 (16) 16 (15.3) NS
 D_, n (%) 42 (84) 89 (84.7)
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fact, studies performed in several countries have con-
firmed this association [22, 28–30]. In a Japanese popula-
tion, one study found higher systolic BP in subjects aged 
≥50 years with the ID genotype compared to II carriers, 
and higher diastolic BP in individuals with the ID and DD 
genotypes compared to those with the II genotype [25]. 
Among the possible explanations for these differences, 
is that BP increases with age, which may have influenced 
the polymorphism studied [42].
In the current study, an association was found between 
the D allele and higher systolic BP during wakefulness 
and during 24-h ABPM in treated patients, results that 
are not supported by some other authors [21, 23, 41]. On 
the other hand, higher BP levels were demonstrated for 
Table 3 Distribution of studied variables according to the genotypes of the ACE I/D polymorphism
Italic values are significant (p < 0.05)
BMI body mass index, LVH left ventricular hypertrophy, ACE I/D angiotensin‑converting enzyme insertion/deletion polymorphism, DBP diastolic blood pressure, SBP 
systolic blood pressure, LV left ventricle, NS non‑significant (p > 0.05)
a Information about II genotype
b Information about ID genotype
c Information about DD genotype
d Information about DD + ID genotypes
a × b × c Statistical analysis among the groups
a × d Statistical analysis between II genotype and sum of ID + DD genotypes




Age (years) 61.7 ± 11.9 63.1 ± 10.6 64.3 ± 12.6 NS 63.5 ± 11.3 NS
Gender (male/female) 8/16 41/46 17/27 NS 58/73 NS
Duration of hypertension (years) 16.9 ± 9.9 15.9 ± 10.0 15.7 ± 10.6 NS 15.8 ± 10.2 NS
BMI (kg/m2) 27.8 ± 4.0 29.1 ± 4.7 28.8 ± 5.7 NS 29.0 ± 5.1 NS
History of stroke, n (%) 9 (37.5) 17 (19.5) 9 (20.5) NS 26 (19.8) NS
History of myocardial infarction, n (%) 0 (0.0) 5 (5.8) 2 (4.5) NS 7 (5.3) NS
LVH, n (%) 3 (13.0) 29 (34.1) 20 (46.5) 0.024 49 (37.4) 0.019
Microalbuminuria, n (%) 14 (58.3) 54 (62.0) 22 (50.0) NS 76 (58.0) NS
Albuminuria (µg/min) 30.9 ± 29.8 27.7 ± 24.9 46.3 ± 75.0 NS 34.1 ± 48.9 NS
Drugs
 Hypolipemiant, n (%) 10 (41.7) 37 (42.5) 24 (54.5) NS 61 (46.6) NS
 Aspirin,  n (%) 9 (37.5) 33 (37.9) 17 (38.6) NS 50 (38.2) NS
 Diuretic, n (%) 21 (87.5) 71 (82.6) 37 (84.1) NS 108 (83.1) NS
 ACE inhibitor,  n (%) 17 (70.8) 58 (66.7) 28 (63.6) NS 86 (65.7) NS
 Angiotensin II receptor antagonist,  n (%) 2 (8.3) 17 (19.5) 3 (6.8) NS 20 (15.3) NS
 Calcium channel blocker,  n (%) 10 (41.7) 36 (41.4) 19 (43.2) NS 55 (42.0) NS
 Beta‑blocker,  n (%) 8 (33.3) 28 (32.2) 10 (22.7) NS 38 (29.0) NS
Blood pressure levels
 24‑h SBP (mmHg) 129.9 ± 12.6 134.8 ± 16.7 139.1 ± 20.1 NS 136.2 ± 18.0 0.042
 24‑h DBP (mmHg) 79.3 ± 5.9 81.7 ± 10.5 82.9 ± 13.7 NS 82.1 ± 11.7 NS
 Daytime SBP (mmHg) 131.8 ± 12.7 136.5 ± 17.1 142.2 ± 19.9 NS 138.4 ± 18.2 0.036
 Daytime DBP (mmHg) 80.0 ± 9.4 84.0 ± 11.0 85.2 ± 13.9 NS 84.4 ± 12.0 NS
 Nighttime SBP (mmHg) 123.8 ± 15.4 129.2 ± 19.0 131.4 ± 21.2 NS 130.0 ± 19.7 NS
 Nighttime DBP (mmHg) 73.2 ± 7.0 75.5 ± 11.6 75.6 ± 14.2 NS 75.6 ± 12.5 NS
 SBP dipping (%) 5.5 ± 7.9 5.3 ± 8.0 6.9 ± 9.0 NS 5.9 ± 8.4 NS
 DBP dipping (%) 8.7 ± 9.0 9.7 ± 9.0 10.9 ± 9.5 NS 10.2 ± 9.2 NS
Echocardiographic profile
 Septal thickness (mm) 9.2 ± 1.1 10.4 ± 1.8 10.0 ± 1.7 0.007 10.3 ± 1.8 <0.001
 Wall thickness (mm) 8.7 ± 1.1 10.2 ± 3.6 9.6 ± 1.6 NS 10.0 ± 3.1 <0.001
 LV mass (g) 170.1 ± 48.0 213.3 ± 95.1 201.4 ± 68.9 NS 209.3 ± 87.1 0.003
 LV mass index (g/m2) 100.3 ± 25.7 120.1 ± 57.0 111.7 ± 31.7 NS 117.3 ± 50.0 0.017
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all evaluated periods (wake, sleep and 24-h) in elderly 
hypertensive Japanese patients who had the D allele [43]. 
In addition, Julve et  al. [44] reported slightly higher BP 
levels in patients with the DD genotype, due to higher 
BP during the nighttime and thus less nocturnal dip-
ping. Although some authors demonstrated this associa-
tion only in males [22, 45], the authors of a meta-analysis 
found 79 % greater risk of hypertension in females with 
the DD compared to those with the II genotype [13].
In the present study, the ACE I/D polymorphism had 
no influence on ND, which corroborates the results of 
other authors [21, 23] although one study demonstrated 
a smaller drop between awake and sleep BP in hyperten-
sive patients with the DD genotype in comparison to car-
riers of the I allele [44]. In addition, there was no effect 
of ACE I/D polymorphism or serum ACE levels on circa-
dian variability of blood pressures among pediatric renal 
transplant patients [46] and in patients with type 1 diabe-
tes [47].
In relation to the association between the ACE I/D 
polymorphism and TOD in hypertensive individuals, 
the current research shows that individuals with the DD 
genotype had an almost fivefold higher risk for LVH com-
pared to those with the II genotype, a condition reported 
by previous studies [10, 11]. Recently, two meta-analyses 
demonstrated an association between the ACE I/D poly-
morphism and LVH [20, 48]. However, other authors did 
not confirm this association [49, 50]. These conflicting 
results may reflect the influence of ethnicity, comorbidi-
ties, and even of antihypertensive treatment on the ACE 
I/D polymorphism and TOD associated with HT.
There is evidence that hypertensive patients with the 
DD genotype present the best antihypertensive response 
to medications, especially in respect to renin–angioten-
sin system (RAS) blockers [51, 52]. These studies demon-
strated a genetic influence on response to BP treatment, 
and the effect of RAS blockers on the regression of LVH. 
Recently, another investigation demonstrated indi-
viduals presented with emergency hypertensive (HE) 
characterized by TOD had a lower frequency of the II 
genotype and less use of RAS blockers when compared 
with the hypertensive urgency group, characterized as 
no TOD. Thus, the risk of an individual having HE was 
increased in the presence of these two conditions (low 
frequency of the II genotype and less use of RAS block-
ers) [18]. On the other hand, one study demonstrated the 
effect of ramipril in inflammatory response in patients 
undergoing coronary artery bypass grafts without the 
ACE I/D gene polymorphism influence [53].
It is known that TOD is more related to the mean 24-h 
BP levels than office BP levels [1, 2], which highlights the 
need for ABPM to evaluate hypertensive patients. The 
absence of ND seems to correlate with TOD in hyperten-
sive individuals [54], although this result was not found 
in the current study.
In the present study, the DD genotype was associ-
ated to higher risk of LVH compared to the II genotype, 
which suggests that the ACE I/D polymorphism may be 
more important than ND in the genesis of LVH. In favor 
of this hypothesis, the results of a meta-analysis found a 
greater risk for LVH associated with the D allele or DD 
genotype in untreated hypertensive patients [20]. In 
addition, DD genotype was also independently associ-
ated with worse echocardiographic outcome in patients 
with non-ischemic heart failure [55]. This is related to an 
increased neurohormonal response, mainly of the renin–
angiotensin aldosterone system [56]. So, it is important 
to point that LVH is an early TOD associated to cardiac 
insufficiency. These facts suggest that independent of the 
treatment, LVH occurs more frequently in individuals 
with the D allele or DD genotype. Thus, it is important to 
highlight that it is possible to detect the impact of genetic 
load on the cardiac phenotype, even with pharmacologi-
cal treatment.
Some limitations of this study should be mentioned. 
First, the size of the sample was small, in part, because of 
the difficulty to select patients due to the exclusion crite-
ria. Second, it was not possible to exclude patients with 
obstructive sleep apnea, a fact that may influence the 
frequency of LVH. However, we have excluded patients 
with BMI ≥35  kg/m2, which reduces greatly the possi-
bility of sleep apnea. Finally, the lack of a control group 
of normotensive individuals, in our viewpoint, was the 
main limitation of this study. Besides, we can cite two 
strong points. The study population was separated in two 
groups, according to nocturnal dipping and the investiga-
tion of influence of the ACE I/D polymorphism on 24-h 
BP levels and on target organ damage.
Conclusions
To our knowledge, this is the first study that evaluates 
the ACE I/D polymorphism in respect to ABPM and 
Table 4 Logistic regression model for  left ventricular 
hypertrophy according to the genotypes of the ACE I/D
Italic values are significant (p < 0.05)
ACE I/D angiotensin‑converting enzyme insertion/deletion polymorphism, LVH 
left ventricular hypertrophy, NS non‑significant (p > 0.05) p<0.05 significant
Variable β Standard 
error
Odds ratio (95 % 
CI)
p value
LVH (II as reference) 1.00
 ID 1.239 0.660 3.45 (0.95–12.59) NS
 DD 1.757 0.690 5.80 (1.50–22.44) 0.011
LVH (II as reference) 1.00
 DD + ID 1.419 0.645 4.14 (1.17–14.65) 0.028
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TOD in Brazilian hypertensive patients. The present 
study reports two findings: the presence of the D allele 
of the ACE I/D polymorphism is correlated with higher 
mean 24-h systolic BP and wake systolic BP, and the DD 
genotype is associated with higher prevalence of LVH in 
non-diabetic hypertensive patients on antihypertensive 
treatment.
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